The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Michael A. Pfaller

Medical Microbiology Division

Department of Pathology

University of Iowa College of Medicine

Iowa City

USA

[email]@uiowa.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Medical Microbiology Division, Department of Pathology, University of Iowa College of Medicine, Iowa City, USA. 1998 - 2012
  • University of Iowa, Iowa City, United States. 2010 - 2011
  • JMI Laboratories, North Liberty, IA 52317, USA. 2011
  • Molecular Epidemiology and Fungus Testing Laboratory, Section of Medical Microbiology, Department of Pathology, Carver College of Medicine, USA. 2005

References

  1. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Pfaller, M.A. Am. J. Med. (2012) [Pubmed]
  2. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Pfaller, M.A., Diekema, D.J., Andes, D., Arendrup, M.C., Brown, S.D., Lockhart, S.R., Motyl, M., Perlin, D.S. Drug Resist. Updat. (2011) [Pubmed]
  3. Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing with the 24-hour CLSI BMD method for testing susceptibility of Candida species to fluconazole, posaconazole, and voriconazole by use of epidemiological cutoff values. Pfaller, M.A., Espinel-Ingroff, A., Boyken, L., Hollis, R.J., Kroeger, J., Messer, S.A., Tendolkar, S., Diekema, D.J. J. Clin. Microbiol. (2011) [Pubmed]
  4. Comparison of the broth microdilution methods of the European Committee on Antimicrobial Susceptibility Testing and the Clinical and Laboratory Standards Institute for testing itraconazole, posaconazole, and voriconazole against Aspergillus isolates. Pfaller, M., Boyken, L., Hollis, R., Kroeger, J., Messer, S., Tendolkar, S., Diekema, D. J. Clin. Microbiol. (2011) [Pubmed]
  5. Validation of 24-hour posaconazole and voriconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: application of epidemiological cutoff values to results from a global Candida antifungal surveillance program. Pfaller, M.A., Boyken, L.B., Hollis, R.J., Kroeger, J., Messer, S.A., Tendolkar, S., Diekema, D.J. J. Clin. Microbiol. (2011) [Pubmed]
  6. Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution. Pfaller, M.A., Boyken, L., Hollis, R.J., Kroeger, J., Messer, S.A., Tendolkar, S., Diekema, D.J. J. Clin. Microbiol. (2011) [Pubmed]
  7. Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Aspergillus species to the triazoles. Pfaller, M., Boyken, L., Hollis, R., Kroeger, J., Messer, S., Tendolkar, S., Diekema, D. J. Clin. Microbiol. (2011) [Pubmed]
  8. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). Pfaller, M.A., Castanheira, M., Messer, S.A., Moet, G.J., Jones, R.N. Diagn. Microbiol. Infect. Dis. (2011) [Pubmed]
  9. Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin, caspofungin, and micafungin. Pfaller, M., Boyken, L., Hollis, R., Kroeger, J., Messer, S., Tendolkar, S., Diekema, D. J. Clin. Microbiol. (2011) [Pubmed]
  10. In vitro activity of anidulafungin and other agents against esophageal candidiasis-associated isolates from a phase 3 clinical trial. Pfaller, M.A., Hollis, R., Goldstein, B.P., Messer, S., Diekema, D., Henkel, T. J. Clin. Microbiol. (2010) [Pubmed]
  11. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. Pfaller, M.A., Boyken, L., Hollis, R.J., Kroeger, J., Messer, S.A., Tendolkar, S., Jones, R.N., Turnidge, J., Diekema, D.J. J. Clin. Microbiol. (2010) [Pubmed]
  12. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species. Pfaller, M.A., Castanheira, M., Diekema, D.J., Messer, S.A., Moet, G.J., Jones, R.N. J. Clin. Microbiol. (2010) [Pubmed]
  13. Wild-type minimum effective concentration distributions and epidemiologic cutoff values for caspofungin and Aspergillus spp. as determined by Clinical and Laboratory Standards Institute broth microdilution methods. Pfaller, M.A., Boyken, L., Hollis, R.J., Kroeger, J., Messer, S.A., Tendolkar, S., Diekema, D.J. Diagn. Microbiol. Infect. Dis. (2010) [Pubmed]
  14. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. Pfaller, M.A., Diekema, D.J., Gibbs, D.L., Newell, V.A., Ellis, D., Tullio, V., Rodloff, A., Fu, W., Ling, T.A. J. Clin. Microbiol. (2010) [Pubmed]
  15. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Pfaller, M.A., Andes, D., Diekema, D.J., Espinel-Ingroff, A., Sheehan, D. Drug Resist. Updat. (2010) [Pubmed]
  16. Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the ARTEMIS DISK Global Antifungal Surveillance Program. Pfaller, M.A., Diekema, D.J., Gibbs, D.L., Newell, V.A., Barton, R., Bijie, H., Bille, J., Chang, S.C., da Luz Martins, M., Duse, A., Dzierzanowska, D., Ellis, D., Finquelievich, J., Gould, I., Gur, D., Hoosen, A., Lee, K., Mallatova, N., Mallie, M., Peng, N.G., Petrikos, G., Santiago, A., Trupl, J., VanDen Abeele, A.M., Wadula, J., Zaidi, M. Diagn. Microbiol. Infect. Dis. (2010) [Pubmed]
  17. Epidemiology of invasive mycoses in North America. Pfaller, M.A., Diekema, D.J. Crit. Rev. Microbiol. (2010) [Pubmed]
  18. In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method. Pfaller, M.A., Boyken, L., Hollis, R.J., Kroeger, J., Messer, S.A., Tendolkar, S., Diekema, D.J. J. Clin. Microbiol. (2009) [Pubmed]
  19. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. Pfaller, M.A., Diekema, D.J., Gibbs, D.L., Newell, V.A., Bijie, H., Dzierzanowska, D., Klimko, N.N., Letscher-Bru, V., Lisalova, M., Muehlethaler, K., Rennison, C., Zaidi, M. J. Clin. Microbiol. (2009) [Pubmed]
  20. Comparison of results of fluconazole and voriconazole disk diffusion testing for Candida spp. with results from a central reference laboratory in the ARTEMIS DISK Global Antifungal Surveillance Program. Pfaller, M.A., Boyken, L., Hollis, R.J., Kroeger, J., Messer, S.A., Tendolkar, S., Diekema, D.J. Diagn. Microbiol. Infect. Dis. (2009) [Pubmed]
  21. Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens. Pfaller, M.A., Messer, S.A., Georgopapadakou, N., Martell, L.A., Besterman, J.M., Diekema, D.J. J. Clin. Microbiol. (2009) [Pubmed]
  22. Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods. Pfaller, M.A., Diekema, D.J., Ghannoum, M.A., Rex, J.H., Alexander, B.D., Andes, D., Brown, S.D., Chaturvedi, V., Espinel-Ingroff, A., Fowler, C.L., Johnson, E.M., Knapp, C.C., Motyl, M.R., Ostrosky-Zeichner, L., Sheehan, D.J., Walsh, T.J. J. Clin. Microbiol. (2009) [Pubmed]
  23. Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007. Pfaller, M.A., Messer, S.A., Hollis, R.J., Boyken, L., Tendolkar, S., Kroeger, J., Diekema, D.J. J. Clin. Microbiol. (2009) [Pubmed]
  24. Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. Pfaller, M.A., Diekema, D.J., Gibbs, D.L., Newell, V.A., Ng, K.P., Colombo, A., Finquelievich, J., Barnes, R., Wadula, J. J. Clin. Microbiol. (2008) [Pubmed]
  25. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. Pfaller, M.A., Diekema, D.J., Ostrosky-Zeichner, L., Rex, J.H., Alexander, B.D., Andes, D., Brown, S.D., Chaturvedi, V., Ghannoum, M.A., Knapp, C.C., Sheehan, D.J., Walsh, T.J. J. Clin. Microbiol. (2008) [Pubmed]
  26. Clinical evaluation of the Sensititre YeastOne colorimetric antifungal panel for antifungal susceptibility testing of the echinocandins anidulafungin, caspofungin, and micafungin. Pfaller, M.A., Chaturvedi, V., Diekema, D.J., Ghannoum, M.A., Holliday, N.M., Killian, S.B., Knapp, C.C., Messer, S.A., Miskov, A., Ramani, R. J. Clin. Microbiol. (2008) [Pubmed]
  27. Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. Pfaller, M.A., Diekema, D.J., Gibbs, D.L., Newell, V.A., Nagy, E., Dobiasova, S., Rinaldi, M., Barton, R., Veselov, A. J. Clin. Microbiol. (2008) [Pubmed]
  28. Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program. Pfaller, M.A., Messer, S.A., Boyken, L., Tendolkar, S., Hollis, R.J., Diekema, D.J. J. Clin. Microbiol. (2008) [Pubmed]
  29. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. Pfaller, M.A., Boyken, L., Hollis, R.J., Kroeger, J., Messer, S.A., Tendolkar, S., Diekema, D.J. J. Clin. Microbiol. (2008) [Pubmed]
  30. In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. Pfaller, M.A., Messer, S.A., Boyken, L., Rice, C., Tendolkar, S., Hollis, R.J., Diekema, D.J. J. Clin. Microbiol. (2008) [Pubmed]
  31. Validation of 24-hour fluconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: results from a global Candida antifungal surveillance program. Pfaller, M.A., Boyken, L.B., Hollis, R.J., Kroeger, J., Messer, S.A., Tendolkar, S., Diekema, D.J. J. Clin. Microbiol. (2008) [Pubmed]
  32. Multicenter comparison of the VITEK 2 yeast susceptibility test with the CLSI broth microdilution reference method for testing fluconazole against Candida spp. Pfaller, M.A., Diekema, D.J., Procop, G.W., Rinaldi, M.G. J. Clin. Microbiol. (2007) [Pubmed]
  33. Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp. Pfaller, M.A., Diekema, D.J., Procop, G.W., Rinaldi, M.G. J. Clin. Microbiol. (2007) [Pubmed]
  34. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. Pfaller, M.A., Diekema, D.J., Gibbs, D.L., Newell, V.A., Meis, J.F., Gould, I.M., Fu, W., Colombo, A.L., Rodriguez-Noriega, E. J. Clin. Microbiol. (2007) [Pubmed]
  35. Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. Tested by clinical and laboratory standards institute-recommended broth microdilution methods. Pfaller, M.A., Messer, S.A., Boyken, L., Rice, C., Tendolkar, S., Hollis, R.J., Diekema, D.J. J. Clin. Microbiol. (2007) [Pubmed]
  36. Epidemiology of invasive candidiasis: a persistent public health problem. Pfaller, M.A., Diekema, D.J. Clin. Microbiol. Rev. (2007) [Pubmed]
  37. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. Pfaller, M.A., Boyken, L., Hollis, R.J., Messer, S.A., Tendolkar, S., Diekema, D.J. J. Clin. Microbiol. (2006) [Pubmed]
  38. Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods. Pfaller, M.A., Boyken, L., Hollis, R.J., Messer, S.A., Tendolkar, S., Diekema, D.J. J. Clin. Microbiol. (2006) [Pubmed]
  39. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. Pfaller, M.A., Diekema, D.J., Rex, J.H., Espinel-Ingroff, A., Johnson, E.M., Andes, D., Chaturvedi, V., Ghannoum, M.A., Odds, F.C., Rinaldi, M.G., Sheehan, D.J., Troke, P., Walsh, T.J., Warnock, D.W. J. Clin. Microbiol. (2006) [Pubmed]
  40. Overview of the epidemiological profile and laboratory detection of extended-spectrum beta-lactamases. Pfaller, M.A., Segreti, J. Clin. Infect. Dis. (2006) [Pubmed]
  41. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Pfaller, M.A., Diekema, D.J., Sheehan, D.J. Clin. Microbiol. Rev. (2006) [Pubmed]
  42. Performance accuracy of antibacterial and antifungal susceptibility test methods: report from the College of American Pathologists Microbiology Surveys Program (2001-2003). Pfaller, M.A., Jones, R.N. Arch. Pathol. Lab. Med. (2006) [Pubmed]
  43. Review of in vitro activity of sertaconazole nitrate in the treatment of superficial fungal infections. Pfaller, M.A., Sutton, D.A. Diagn. Microbiol. Infect. Dis. (2006) [Pubmed]
  44. Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program. Pfaller, M.A., Diekema, D.J., Mendez, M., Kibbler, C., Erzsebet, P., Chang, S.C., Gibbs, D.L., Newell, V.A. J. Clin. Microbiol. (2006) [Pubmed]
  45. Candida rugosa, an emerging fungal pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program. Pfaller, M.A., Diekema, D.J., Colombo, A.L., Kibbler, C., Ng, K.P., Gibbs, D.L., Newell, V.A. J. Clin. Microbiol. (2006) [Pubmed]
  46. Unusual fungal and pseudofungal infections of humans. Pfaller, M.A., Diekema, D.J. J. Clin. Microbiol. (2005) [Pubmed]
  47. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). Pfaller, M.A., Messer, S.A., Boyken, L., Rice, C., Tendolkar, S., Hollis, R.J., Doern, G.V., Diekema, D.J. J. Clin. Microbiol. (2005) [Pubmed]
  48. In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methods. Pfaller, M.A., Boyken, L., Hollis, R.J., Messer, S.A., Tendolkar, S., Diekema, D.J. J. Clin. Microbiol. (2005) [Pubmed]
  49. Comparison of results of voriconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program. Pfaller, M.A., Boyken, L., Messer, S.A., Tendolkar, S., Hollis, R.J., Diekema, D.J. J. Clin. Microbiol. (2005) [Pubmed]
  50. Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis. Pfaller, M.A., Diekema, D.J., Boyken, L., Messer, S.A., Tendolkar, S., Hollis, R.J., Goldstein, B.P. Antimicrob. Agents Chemother. (2005) [Pubmed]
  51. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. Pfaller, M.A., Boyken, L., Hollis, R.J., Messer, S.A., Tendolkar, S., Diekema, D.J. J. Clin. Microbiol. (2005) [Pubmed]
  52. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. Pfaller, M.A., Diekema, D.J., Rinaldi, M.G., Barnes, R., Hu, B., Veselov, A.V., Tiraboschi, N., Nagy, E., Gibbs, D.L. J. Clin. Microbiol. (2005) [Pubmed]
  53. Antifungal susceptibility testing methods. Pfaller, M.A. Curr. Drug. Targets (2005) [Pubmed]
  54. Evaluation of the NCCLS M44-P disk diffusion method for determining susceptibilities of 276 clinical isolates of Cryptococcus neoformans to fluconazole. Pfaller, M.A., Messer, S.A., Boyken, L., Rice, C., Tendolkar, S., Hollis, R.J., Diekema, D.J. J. Clin. Microbiol. (2004) [Pubmed]
  55. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Pfaller, M.A., Diekema, D.J. Clin. Microbiol. Infect. (2004) [Pubmed]
  56. In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents. Pfaller, M.A., Diekema, D.J., Messer, S.A., Boyken, L., Hollis, R.J., Jones, R.N. Diagn. Microbiol. Infect. Dis. (2004) [Pubmed]
  57. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Pfaller, M.A., Messer, S.A., Boyken, L., Hollis, R.J., Rice, C., Tendolkar, S., Diekema, D.J. Diagn. Microbiol. Infect. Dis. (2004) [Pubmed]
  58. Quality control limits for voriconazole disk susceptibility tests on Mueller-Hinton agar with glucose and methylene blue. Pfaller, M.A., Barry, A., Bille, J., Brown, S., Ellis, D., Meis, J.F., Rennie, R., Rinaldi, M., Rogers, T., Traczewski, M. J. Clin. Microbiol. (2004) [Pubmed]
  59. Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization. Pfaller, M.A., Sheehan, D.J., Rex, J.H. Clin. Microbiol. Rev. (2004) [Pubmed]
  60. Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates. Pfaller, M.A., Messer, S.A., Boyken, L., Rice, C., Tendolkar, S., Hollis, R.J., Diekema, D.J. J. Clin. Microbiol. (2004) [Pubmed]
  61. Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida spp. Pfaller, M.A., Messer, S.A., Boyken, L., Rice, C., Tendolkar, S., Hollis, R.J., Diekema, D.J. J. Clin. Microbiol. (2004) [Pubmed]
  62. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. Pfaller, M.A., Messer, S.A., Boyken, L., Tendolkar, S., Hollis, R.J., Diekema, D.J. J. Clin. Microbiol. (2004) [Pubmed]
  63. Comparison of results of fluconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program. Pfaller, M.A., Hazen, K.C., Messer, S.A., Boyken, L., Tendolkar, S., Hollis, R.J., Diekema, D.J. J. Clin. Microbiol. (2004) [Pubmed]
  64. Anidulafungin: an echinocandin antifungal. Pfaller, M.A. Expert. Opin. Investig. Drugs (2004) [Pubmed]
  65. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. Pfaller, M.A., Diekema, D.J. J. Clin. Microbiol. (2004) [Pubmed]
  66. Clinical evaluation of the Sensititre YeastOne colorimetric antifungal plate for antifungal susceptibility testing of the new triazoles voriconazole, posaconazole, and ravuconazole. Pfaller, M.A., Espinel-Ingroff, A., Jones, R.N. J. Clin. Microbiol. (2004) [Pubmed]
  67. Clinical evaluation of a dried commercially prepared microdilution panel for antifungal susceptibility testing of five antifungal agents against Candida spp. and Cryptococcus neoformans. Pfaller, M.A., Boyken, L., Hollis, R.J., Messer, S.A., Tendolkar, S., Diekema, D.J. Diagn. Microbiol. Infect. Dis. (2004) [Pubmed]
  68. Evaluation of the etest method using Mueller-Hinton agar with glucose and methylene blue for determining amphotericin B MICs for 4,936 clinical isolates of Candida species. Pfaller, M.A., Boyken, L., Messer, S.A., Tendolkar, S., Hollis, R.J., Diekema, D.J. J. Clin. Microbiol. (2004) [Pubmed]
  69. In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood. Pfaller, M.A., Diekema, D.J., Messer, S.A., Boyken, L., Hollis, R.J., Jones, R.N. J. Clin. Microbiol. (2003) [Pubmed]
  70. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. Pfaller, M.A., Diekema, D.J., Messer, S.A., Hollis, R.J., Jones, R.N. Antimicrob. Agents Chemother. (2003) [Pubmed]
  71. Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001. Pfaller, M.A., Diekema, D.J., Messer, S.A., Boyken, L., Hollis, R.J. J. Clin. Microbiol. (2003) [Pubmed]
  72. In vitro susceptibility testing of filamentous fungi: comparison of Etest and reference M38-A microdilution methods for determining posaconazole MICs. Pfaller, M.A., Messer, S.A., Boyken, L., Hollis, R.J., Diekema, D.J. Diagn. Microbiol. Infect. Dis. (2003) [Pubmed]
  73. Evaluation of the Etest and disk diffusion methods for determining susceptibilities of 235 bloodstream isolates of Candida glabrata to fluconazole and voriconazole. Pfaller, M.A., Diekema, D.J., Boyken, L., Messer, S.A., Tendolkar, S., Hollis, R.J. J. Clin. Microbiol. (2003) [Pubmed]
  74. Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location. Pfaller, M.A., Messer, S.A., Boyken, L., Tendolkar, S., Hollis, R.J., Diekema, D.J. J. Clin. Microbiol. (2003) [Pubmed]
  75. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. Pfaller, M.A., Diekema, D.J., Jones, R.N., Messer, S.A., Hollis, R.J. J. Clin. Microbiol. (2002) [Pubmed]
  76. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Pfaller, M.A., Messer, S.A., Hollis, R.J., Jones, R.N. Antimicrob. Agents Chemother. (2002) [Pubmed]
  77. Clinical evaluation of a frozen commercially prepared microdilution panel for antifungal susceptibility testing of seven antifungal agents, including the new triazoles posaconazole, ravuconazole, and voriconazole. Pfaller, M.A., Diekema, D.J., Messer, S.A., Boyken, L., Huynh, H., Hollis, R.J. J. Clin. Microbiol. (2002) [Pubmed]
  78. Antimicrobial susceptibility of inducible AmpC beta-lactamase-producing Enterobacteriaceae from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme, Europe 1997-2000. Pfaller, M.A., Jones, R.N. Int. J. Antimicrob. Agents (2002) [Pubmed]
  79. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Pfaller, M.A., Messer, S.A., Hollis, R.J., Jones, R.N., Diekema, D.J. Antimicrob. Agents Chemother. (2002) [Pubmed]
  80. Gatifloxacin phase IV surveillance trial (TeqCES study) utilizing 5000 primary care physician practices: report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections. Pfaller, M.A., Jones, R.N. Diagn. Microbiol. Infect. Dis. (2002) [Pubmed]
  81. In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods. Pfaller, M.A., Messer, S.A., Boyken, L., Huynh, H., Hollis, R.J., Diekema, D.J. Antimicrob. Agents Chemother. (2002) [Pubmed]
  82. Molecular approaches to diagnosing and managing infectious diseases: practicality and costs. Pfaller, M.A. Emerging Infect. Dis. (2001) [Pubmed]
  83. Integration of molecular characterization of microorganisms in a global antimicrobial resistance surveillance program. Pfaller, M.A., Acar, J., Jones, R.N., Verhoef, J., Turnidge, J., Sader, H.S. Clin. Infect. Dis. (2001) [Pubmed]
  84. Proposed quality control guidelines for National Committee for Clinical Laboratory Standards Susceptibility Tests using the veterinary antimicrobial agent tiamulin. Pfaller, M.A., Jones, R.N., Walter, D.H. Diagn. Microbiol. Infect. Dis. (2001) [Pubmed]
  85. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans. Pfaller, M.A., Messer, S.A., Hollis, R.J., Jones, R.N. Antimicrob. Agents Chemother. (2001) [Pubmed]
  86. Evaluation of Etest method for determining posaconazole MICs for 314 clinical isolates of Candida species. Pfaller, M.A., Messer, S.A., Mills, K., Bolmström, A., Jones, R.N. J. Clin. Microbiol. (2001) [Pubmed]
  87. Evaluation of Etest method for determining caspofungin (MK-0991) susceptibilities of 726 clinical isolates of Candida species. Pfaller, M.A., Messer, S.A., Mills, K., Bolmström, A., Jones, R.N. J. Clin. Microbiol. (2001) [Pubmed]
  88. Antimicrobial resistance trends in medical centers using carbapenems: report of 1999 and 2000 results from the MYSTIC program (USA). Pfaller, M.A., Jones, R.N., Biedenbach, D.J. Diagn. Microbiol. Infect. Dis. (2001) [Pubmed]
  89. Antifungal susceptibility testing. New technology and clinical applications. Pfaller, M.A., Yu, W.L. Infect. Dis. Clin. North Am. (2001) [Pubmed]
  90. Global view of antimicrobial resistance. Findings of the SENTRY Antimicrobial Surveillance Program, 1997-1999. Pfaller, M.A., Jones, R.N. Postgrad. Med (2001) [Pubmed]
  91. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Pfaller, M.A., Jones, R.N., Doern, G.V., Sader, H.S., Messer, S.A., Houston, A., Coffman, S., Hollis, R.J. Antimicrob. Agents Chemother. (2000) [Pubmed]
  92. In vitro susceptibility testing of filamentous fungi: comparison of Etest and reference microdilution methods for determining itraconazole MICs. Pfaller, M.A., Messer, S.A., Mills, K., Bolmström, A. J. Clin. Microbiol. (2000) [Pubmed]
  93. Epidemiology of nosocomial candidiasis: the importance of molecular typing. Pfaller, M.A. Braz. J. Infect. Dis (2000) [Pubmed]
  94. Antifungal susceptibility testing: progress and future developments. Pfaller, M.A. Braz. J. Infect. Dis (2000) [Pubmed]
  95. Evaluation of the Etest method for determining voriconazole susceptibilities of 312 clinical isolates of Candida species by using three different agar media. Pfaller, M.A., Messer, S.A., Houston, A., Mills, K., Bolmstrom, A., Jones, R.N. J. Clin. Microbiol. (2000) [Pubmed]
  96. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections. MYSTIC Study Group (Americas). Pfaller, M.A., Jones, R.N. J. Antimicrob. Chemother. (2000) [Pubmed]
  97. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents. Pfaller, M.A., Messer, S.A., Gee, S., Joly, S., Pujol, C., Sullivan, D.J., Coleman, D.C., Soll, D.R. J. Clin. Microbiol. (1999) [Pubmed]
  98. Evaluation of the Etest method for determining fluconazole susceptibilities of 402 clinical yeast isolates by using three different agar media. Pfaller, M.A., Messer, S.A., Karlsson, A., Bolmström, A. J. Clin. Microbiol. (1998) [Pubmed]
  99. In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole. Pfaller, M.A., Messer, S.A., Hollis, R.J., Jones, R.N., Doern, G.V., Brandt, M.E., Hajjeh, R.A. Antimicrob. Agents Chemother. (1998) [Pubmed]
 
WikiGenes - Universities